While the drop in Ultragenyx stock certainly provides a lower entry point for new investors, the more prudent choice right ...

Discover why pharma sector leaders and AI innovation may drive the S&P 500 to 9,000 by 2026. Explore top stocks, growth ...

For most drugmakers, the US is the largest single market. Prices there are often close to three times higher than in other ...

Novo Nordisk and Eli Lilly are lowering prices of their top-selling obesity drugs Wegovy and Mounjaro in China, according to ...

Several Indian companies are preparing to launch generic versions of GLP-1 category drug Semaglutide in India ...

Ultragenyx Pharmaceutical said on Monday that late-stage studies showed its drug for a type of genetic bone disease failed to ...

Lupin has signed the agreement with China-based Gan & Lee Pharmaceuticals for Bofanglutide. With this, it gets exclusive ...

Ultragenyx Pharmaceutical and Mereo BioPharma said their two Phase 3 trials for setrusumab to treat rare bone disorder osteogenesis imperfecta, didn't meet their main goal of reducing fracture rates.

Explore the challenges faced by Indian pharma in developing rare disease drugs and potential solutions for innovation and cost reduction.

Exploring clinical development plan options including a controlled human infection model (CHIM) and a Phase 2/3 adaptive ...

The Delhi High Court has recently, temeperorily restrained Dr Reddy's Laboratories Ltd. from further manufacturing sunscreen ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the AI stocks under $20 to buy now. On December 8, Recursion ...